U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Guidances | Drugs
  1. Guidance, Compliance, & Regulatory Information

Guidances | Drugs

About FDA Guidances

Guidance documents represent the Agency's current thinking on a particular subject. They do not create or confer any rights for or on any person and do not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both. For information on a specific guidance document, please contact the originating office.  Another method of obtaining guidance documents is through the Division of Drug Information.

 

Search All FDA Guidances

 

Find a guidance related to drugs

  • Go to Search for FDA Guidance Documents
  • Scroll down to Guidance Document Search
  • Filter by FDA Organization, Center for Drug Evaluation and Research
  • Use other filters, as needed
TOPICS Related to Drugs
[Terms in brackets are used in the FDA filter dropdown]
  • Administrative/Procedural
  • Advertising
  • Animal Rule
  • Biopharmaceutics
  • Biosimilars
  • Biostatistics
  • Chemistry, Manufacturing, and Controls (CMC)
  • Clinical/Antimicrobial
  • Clinical/Medical
  • Clinical Pharmacology
  • Combination Products
  • Compliance
  • Compounding
  • Current Good Manufacturing Practice (CGMP)
  • Drug Competition Action Plan
  • Drug Development Tools
  • Drug Safety [Safety - Issues, Errors, and Problems]
  • Electronic Submissions
  • FDA Amendments Act (FDAAA)
  • Food and Drug Administration Modernization Act of 1997
  • Generic Drugs
  • ICH-Efficacy
  • ICH-Multidisciplinary
  • ICH-Safety
  • ICH-Quality
  • Labeling
  • Microbiology
  • Over-the-Counter
  • Pharmaceutical Quality 
  • Pharmacology/Toxicology 
  • Product-Specific Guidances for Generic Drug Development (separate database)
  • Rare Diseases
  • Real World Data/Real World Evidence (RWD/RWE)
  • User Fees

Good Guidance Practices


Contact FDA


Sub-Topic Paragraphs

Quick Links

Guidance Snapshot Pilot

Cross-cutting guidances on topics that seek to modernize drug clinical trials and accelerate drug development


Back to Top